910 studies found for:    Open Studies | "Carcinoma, Bronchogenic"
Show Display Options
Rank Status Study
1 Recruiting SAS in Patients With Bronchial Carcinoma
Conditions: Sleep Apnea Syndrome;   Bronchial Carcinoma
Intervention: Device: sleep apnea screening with ApneaLinkTM
2 Recruiting Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics
Conditions: Tumors;   Carcinoma, Bronchogenic;   Breast Carcinoma;   Cancer of Head and Neck;   Lymphoma, Malignant;   Soft Tissue Neoplasms
Intervention: Drug: 18F-Al-NOTA-PRGD2 PET/CT
3 Unknown  Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
Condition: Squamous Cell Carcinoma of Bronchus
Intervention: Drug: Gefitinib
4 Unknown  Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)
Condition: Recurrent Small Cell Lung Cancer
Intervention: Drug: Bendamustin/Ribomustin
5 Recruiting Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer
Conditions: Stage IA Non-small Cell Lung Cancer;   Adenocarcinoma of the Lung;   Squamous Cell Lung Cancer
6 Recruiting Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
Conditions: Lung Cancer;   Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dasatinib - 1A;   Drug: Afatinib - 1A;   Drug: Dasatinib - 1B;   Drug: Afatinib - 1B
7 Recruiting Identification by Microarrays of the Risks of Metastatic Relapse, Toxicity and Resistance to Adjuvant Chemotherapy in Completely Resected Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
8 Recruiting A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib and Erlotinib, in Non-small Cell Lung Cancer(NSCLC)Treatment
Conditions: Non-small Cell Lung Cancer (NSCLC);;   EGFR-TKI Resistant Mutation;;   EGFR-TKI Sensitizing Mutation;;   Germline Mutations
9 Unknown  Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab;   Drug: carboplatin;   Drug: gemcitabine
10 Not yet recruiting Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations
Condition: Non-Small Cell Lung Cancer
Interventions: Radiation: PET-Adaptive RT;   Drug: Erlotinib;   Drug: Crizotinib
11 Unknown  Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer
Condition: Small Cell Lung Cancer
Interventions: Drug: Docetaxel;   Drug: Bevacizumab
12 Recruiting An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement
Condition: Non-small Cell Lung Cancer (NSCLC)
Intervention: Drug: LDK378
13 Recruiting Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
Conditions: EGFR Positive Non-small Cell Lung Cancer;   Adenocarcinoma
Interventions: Drug: Sequential Icotinib Plus Chemotherapy;   Drug: Icotinib
14 Recruiting A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
Condition: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Docetaxel;   Drug: Gemcitabine;   Drug: Lurbinectedin (PM01183)
15 Recruiting Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
Condition: Metastatic Small Cell Lung Cancer
Interventions: Drug: Aldoxorubicin;   Drug: Topotecan
16 Recruiting Pembrolizumab in Treating Patients With Extensive Stage Small Cell Lung Cancer After Completion of Combination Chemotherapy
Condition: Extensive Stage Small Cell Lung Carcinoma
Interventions: Biological: Pembrolizumab;   Other: Laboratory Biomarker Analysis
17 Recruiting RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer
Condition: Small Cell Lung Carcinoma
Interventions: Drug: Roniciclib (BAY1000394);   Drug: Placebo
18 Recruiting Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: HM61713
19 Recruiting Treating NSCLC Minimal Stage IV With Curative Intent
Condition: Non-small Cell Lung Cancer
Interventions: Other: Induction chemotherapy and concurrent radiation;   Other: Consolidation: Radiation therapy to metastatic sites
20 Unknown  Studying Biomarkers in Tumor Tissue and Blood Samples From Patients With Small Cell Lung Cancer Registered on CALGB-140202
Condition: Lung Cancer
Interventions: Genetic: DNA analysis;   Genetic: gene expression analysis;   Genetic: gene mapping;   Genetic: mutation analysis;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years